NBIX Financial Facts
Total revenues: 0Research and development: 20.94M
See Full Income Statement
Deferred gain on sale of real estate: 8.26M
Commitments and contingencies: 0
See Full Balance Sheet
Neurocrine Biosciences Inc. (NBIX) Earnings
|
Expand Research on NBIX
| Next EPS Date | 11/3/26 | EPS Growth Rate | -12.4% |
|---|---|---|---|
| Average EPS % Beat Rate | +45.9% | Revenue Growth Rate | +30.8% |
| Average % Move 1-Wk after EPS | -3.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/3/26  |
Q326 | N/A | $1.90 | N/A | N/A | $1.04B | = | N/A | N/A | ||
| 7/30/26 | Q226 | $2.85 | $1.58 | +$1.27 | $959M | $877.34M | = |  | | Details | |
| 5/5/26 | Q126 | $1.94 | $1.17 | +$0.77 | $811M | $766.85M | = | | | Details | |
| 2/11/26 | Q425 | $1.88 | $1.86 | +$0.02 | $805.5M | $802.45M | = | | | Details | |
| 10/28/25 | Q325 | $2.17 | $1.59 | +$0.58 | $794.9M | $748.62M | = | | | Details | |
| 7/30/25 | Q225 | $1.65 | $0.96 | +$0.69 | $687.5M | $653.32M | = | | | Details | |
| 5/5/25 | Q125 | $0.70 | $0.77 | -$0.07 | $572.6M | $593.71M | = | | | Details | |
| 2/6/25 | Q424 | $1.69 | $1.57 | +$0.12 | $627.7M | $630.01M | = | | | Details |
